Dr  Gough Au

Dr Gough Au

Conjoint Senior Lecturer

School of Biomedical Sciences and Pharmacy (Immunology and Microbiology)

Career Summary

Biography

Dr Gough Au is a conjoint Post Doctoral Research Fellow with the University of Newcastle and works for the Australian oncolytic virotherapy company Viralytics Ltd. Dr Au began his career as a NHMRC Industry Research fellow (2007-2011) carrying out research on the development of naturally occurring viruses with selective anti-cancer properties, for the treatment of melanoma, multiple myeloma and malignant glioma.

Research Expertise
Oncolytic virotherapy, Virology & Cancer Biology

Teaching Expertise
PHAR6124 Virology Lectures HUBS3204 Lab Professional Skills - Commercialisation of Science and Biotechnology Startup Companies.

Administrative Expertise
Animal Care and Ethics Committee member (2011- to present) Faculty of Health - Work Health and Safety Group.

Collaborations
Gough's main research interest is in the development of naturally occurring viruses with selective anti-cancer properties, for the treatment of melanoma, multiple myeloma and malignant glioma. Other interests include Oncolytic virotherapy, Virology and Cancer Biology.


Qualifications

  • PhD, University of Newcastle
  • Bachelor of Biomedical Sciences, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • Carcinogenesis
  • Clinical sciences
  • Oncology
  • oncolytic virotherapy
  • virology

Professional Experience

Academic appointment

Dates Title Organisation / Department
1/5/2007 - 1/4/2011 Fellow University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/5/2007 -  NHMRC Industry Fellow University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/8/2004 - 1/5/2007 Research Director

Research Director/Post Doctoral Scientist

The University of Newcastle Research Associates
School of Biomedical Sciences and Pharmacy
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (26 outputs)

Year Citation Altmetrics Link
2023 Chia WN, Tan CW, Tan AWK, Young B, Starr TN, Lopez E, et al., 'Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor', Science Advances, 9 (2023) [C1]

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern such as Omicron hampered efforts in controlling the ongoing coronavirus disease 2... [more]

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern such as Omicron hampered efforts in controlling the ongoing coronavirus disease 2019 pandemic due to their ability to escape neutralizing antibodies induced by vaccination or prior infection, highlighting the need to develop broad-spectrum vaccines and therapeutics. Most human monoclonal antibodies (mAbs) reported to date have not demonstrated true pan-sarbecovirus neutralizing breadth especially against animal sarbecoviruses. Here, we report the isolation and characterization of highly potent mAbs targeting the receptor binding domain (RBD) of huACE2-dependent sarbecovirus from a SARS-CoV survivor vaccinated with BNT162b2. Among the six mAbs identified, one (E7) showed better huACE2-dependent sarbecovirus neutralizing potency and breadth than any other mAbs reported to date. Mutagenesis and cryo¿electron microscopy studies indicate that these mAbs have a unique RBD contact footprint and that E7 binds to a quaternary structure¿dependent epitope.

DOI 10.1126/sciadv.ade3470
Citations Scopus - 2
2022 Marsh GA, McAuley AJ, Brown S, Pharo EA, Crameri S, Au GG, et al., 'In vitro characterisation of SARS-CoV-2 and susceptibility of domestic ferrets (Mustela putorius furo)', TRANSBOUNDARY AND EMERGING DISEASES, 69 297-307 (2022) [C1]
DOI 10.1111/tbed.13978
Citations Scopus - 10Web of Science - 10
2022 Karpe AV, Nguyen TV, Shah RM, Au GG, McAuley AJ, Marsh GA, et al., 'A Time-Series Metabolomic Analysis of SARS-CoV-2 Infection in a Ferret Model', Metabolites, 12 (2022) [C1]

The global threat of COVID-19 has led to an increased use of metabolomics to study SARS-CoV-2 infections in animals and humans. In spite of these efforts, however, understanding t... [more]

The global threat of COVID-19 has led to an increased use of metabolomics to study SARS-CoV-2 infections in animals and humans. In spite of these efforts, however, understanding the metabolome of SARS-CoV-2 during an infection remains difficult and incomplete. In this study, metabolic responses to a SAS-CoV-2 challenge experiment were studied in nasal washes collected from an asymptomatic ferret model (n = 20) at different time points before and after infection using an LC-MS-based metabolomics approach. A multivariate analysis of the nasal wash metabolome data revealed several statistically significant features. Despite no effects of sex or interaction between sex and time on the time course of SARS-CoV-2 infection, 16 metabolites were significantly different at all time points post-infection. Among these altered metabolites, the relative abundance of taurine was elevated post-infection, which could be an indication of hepatotoxicity, while the accumulation of sialic acids could indicate SARS-CoV-2 invasion. Enrichment analysis identified several pathways influenced by SARS-CoV-2 infection. Of these, sugar, glycan, and amino acid metabolisms were the key altered pathways in the upper respiratory channel during infection. These findings provide some new insights into the progression of SARS-CoV-2 infection in ferrets at the metabolic level, which could be useful for the development of early clinical diagnosis tools and new or repurposed drug therapies.

DOI 10.3390/metabo12111151
Citations Scopus - 1
2022 Au GG, Marsh GA, McAuley AJ, Lowther S, Trinidad L, Edwards S, et al., 'Characterisation and natural progression of SARS-CoV-2 infection in ferrets', Scientific Reports, 12 (2022) [C1]

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the infectious disease COVID-19, which has rapidly become an international pandemic with significan... [more]

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the infectious disease COVID-19, which has rapidly become an international pandemic with significant impact on healthcare systems and the global economy. To assist antiviral therapy and vaccine development efforts, we performed a natural history/time course study of SARS-CoV-2 infection in ferrets to characterise and assess the suitability of this animal model. Ten ferrets of each sex were challenged intranasally with 4.64 × 104 TCID50 of SARS-CoV-2 isolate Australia/VIC01/2020 and monitored for clinical disease signs, viral shedding, and tissues collected post-mortem for histopathological and virological assessment at set intervals. We found that SARS-CoV-2 replicated in the upper respiratory tract of ferrets with consistent viral shedding in nasal wash samples and oral swab samples up until day 9. Infectious SARS-CoV-2 was recovered from nasal washes, oral swabs, nasal turbinates, pharynx, and olfactory bulb samples within 3¿7¿days post-challenge; however, only viral RNA was detected by qRT-PCR in samples collected from the trachea, lung, and parts of the gastrointestinal tract. Viral antigen was seen exclusively in nasal epithelium and associated sloughed cells and draining lymph nodes upon immunohistochemical staining. Due to the absence of clinical signs after viral challenge, our ferret model is appropriate for studying asymptomatic SARS-CoV-2 infections and most suitable for use in vaccine efficacy studies.

DOI 10.1038/s41598-022-08431-6
Citations Scopus - 11Web of Science - 10
2021 Layton D, Burkett K, Marsh GA, Singanallur NB, Barr J, Layton R, et al., 'Type i Hypersensitivity in Ferrets Following Exposure to SARS-CoV-2 Inoculum: Lessons Learned', ILAR Journal, 62 232-237 (2021) [C1]

This case report discusses Type I hypersensitivity in ferrets following exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inoculum, observed during a study ... [more]

This case report discusses Type I hypersensitivity in ferrets following exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inoculum, observed during a study investigating the efficacy of candidate COVID-19 vaccines. Following a comprehensive internal root-cause investigation, it was hypothesized that prior prime-boost immunization of ferrets with a commercial canine C3 vaccine to protect against the canine distemper virus had resulted in primary immune response to fetal bovine serum (FBS) in the C3 preparation. Upon intranasal exposure to SARS-CoV-2 virus cultured in medium containing FBS, an allergic airway response occurred in 6 out of 56 of the ferrets. The 6 impacted ferrets were randomly dispersed across study groups, including different COVID-19 vaccine candidates, routes of vaccine candidate administration, and controls (placebo). The root-cause investigation and subsequent analysis determined that the allergic reaction was unrelated to the COVID-19 vaccine candidates under evaluation. Histological assessment suggested that the allergic response was characterized by eosinophilic airway disease; increased serum immunoglobulin levels reactive to FBS further suggested this response was caused by immune priming to FBS present in the C3 vaccine. This was further supported by in vivo studies demonstrating ferrets administered diluted FBS also presented clinical signs consistent with a hyperallergic response, while clinical signs were absent in ferrets that received a serum-free SARS-CoV-2 inoculum. It is therefore recommended that vaccine studies in higher order animals should consider the impact of welfare vaccination and use serum-free inoculum whenever possible.

DOI 10.1093/ilar/ilab019
Citations Scopus - 2
2021 Farr RJ, Rootes CL, Rowntree LC, Nguyen THO, Hensen L, Kedzierski L, et al., 'Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection', PLoS Pathogens, 17 (2021) [C1]

The host response to SARS-CoV-2 infection provide insights into both viral pathogenesis and patient management. The host-encoded microRNA (miRNA) response to SARS-CoV-2 infection,... [more]

The host response to SARS-CoV-2 infection provide insights into both viral pathogenesis and patient management. The host-encoded microRNA (miRNA) response to SARS-CoV-2 infection, however, remains poorly defined. Here we profiled circulating miRNAs from ten COVID-19 patients sampled longitudinally and ten age and gender matched healthy donors. We observed 55 miRNAs that were altered in COVID-19 patients during early-stage disease, with the inflammatory miR-31-5p the most strongly upregulated. Supervised machine learning analysis revealed that a three-miRNA signature (miR-423-5p, miR-23a-3p and miR-195-5p) independently classified COVID-19 cases with an accuracy of 99.9%. In a ferret COVID-19 model, the three-miRNA signature again detected SARS-CoV-2 infection with 99.7% accuracy, and distinguished SARS-CoV-2 infection from influenza A (H1N1) infection and healthy controls with 95% accuracy. Distinct miRNA profiles were also observed in COVID-19 patients requiring oxygenation. This study demonstrates that SARS-CoV-2 infection induces a robust host miRNA response that could improve COVID-19 detection and patient management.

DOI 10.1371/journal.ppat.1009759
Citations Scopus - 97
2021 Murray HC, Enjeti AK, Kahl RGS, Flanagan HM, Sillar J, Skerrett-Byrne DA, et al., 'Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia', LEUKEMIA, 35 1782-1787 (2021)
DOI 10.1038/s41375-020-01050-y
Citations Scopus - 22Web of Science - 15
Co-authors Brett Nixon, Heather Murray, David Skerrett-Byrne, Matt Dun, Anoop Enjeti, Nikki Verrills
2021 Marsh GA, McAuley AJ, Au GG, Riddell S, Layton D, Singanallur NB, et al., 'ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets', NPJ VACCINES, 6 (2021) [C1]
DOI 10.1038/s41541-021-00315-6
Citations Scopus - 29Web of Science - 25
2021 Beale DJ, Shah R, Karpe A, Hillyer KE, McAuley AJ, Au GG, et al., 'Metabolic Profiling from an Asymptomatic Ferret Model of SARS-CoV-2 Infection', METABOLITES, 11 (2021) [C1]
DOI 10.3390/metabo11050327
Citations Scopus - 21Web of Science - 9
2021 Harrison AR, Todd S, Dearnley M, David CT, Green D, Rawlinson SM, et al., 'Antagonism of STAT3 signalling by Ebola virus', PLOS PATHOGENS, 17 (2021) [C1]
DOI 10.1371/journal.ppat.1009636
Citations Scopus - 6Web of Science - 5
2020 McAuley AJ, Kuiper MJ, Durr PA, Bruce MP, Barr J, Todd S, et al., 'Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein', npj Vaccines, 5 (2020) [C1]

The ¿D614G¿ mutation (Aspartate-to-Glycine change at position 614) of the SARS-CoV-2 spike protein has been speculated to adversely affect the efficacy of most vaccines and counte... [more]

The ¿D614G¿ mutation (Aspartate-to-Glycine change at position 614) of the SARS-CoV-2 spike protein has been speculated to adversely affect the efficacy of most vaccines and countermeasures that target this glycoprotein, necessitating frequent vaccine matching. Virus neutralisation assays were performed using sera from ferrets which received two doses of the INO-4800 COVID-19 vaccine, and Australian virus isolates (VIC01, SA01 and VIC31) which either possess or lack this mutation but are otherwise comparable. Through this approach, supported by biomolecular modelling of this mutation and the commonly-associated P314L mutation in the RNA-dependent RNA polymerase, we have shown that there is no experimental evidence to support this speculation. We additionally demonstrate that the putative elastase cleavage site introduced by the D614G mutation is unlikely to be accessible to proteases.

DOI 10.1038/s41541-020-00246-8
Citations Scopus - 46Web of Science - 35
2019 Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M, et al., 'Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer', CLINICAL CANCER RESEARCH, 25 5818-5831 (2019)
DOI 10.1158/1078-0432.CCR-18-4022
Citations Scopus - 83Web of Science - 56
2018 Annels NE, Arif M, Simpson GR, Denyer M, Moller-Levet C, Mansfield D, et al., 'Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus', MOLECULAR THERAPY-ONCOLYTICS, 9 1-12 (2018)
DOI 10.1016/j.omto.2018.02.001
Citations Scopus - 44Web of Science - 45
2017 Sahoo SS, Quah MY, Nielsen S, Atkins J, Au GG, Cairns MJ, et al., 'Inhibition of extracellular matrix mediated TGF-ß signalling suppresses endometrial cancer metastasis.', Oncotarget, 8 (2017) [C1]
DOI 10.18632/oncotarget.18069
Citations Scopus - 21Web of Science - 17
Co-authors Pradeep Tanwar, Murray Cairns
2016 Pandha HS, Annels N, Arif M, Mostafid H, Sandhu S, Harrington K, et al., 'Phase I/II CANON study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21', Annals of Oncology, 27 vi361 (2016)
DOI 10.1093/annonc/mdw378.09
Citations Scopus - 3
2014 McIlroy DJ, Jarnicki AG, Au GG, Lott N, Smith DW, Hansbro PM, Balogh ZJ, 'Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery', Journal of Critical Care, 29 1133.e1-1133.e5 (2014) [C1]

Introduction: Neutrophil extracellular traps (NETs) have not been demonstrated after trauma and subsequent surgery. Neutrophil extracellular traps are formed from pure mitochondri... [more]

Introduction: Neutrophil extracellular traps (NETs) have not been demonstrated after trauma and subsequent surgery. Neutrophil extracellular traps are formed from pure mitochondrial DNA (mtDNA) under certain conditions, which is potently proinflammatory. We hypothesized that injury and orthopedic trauma surgery would induce NET production with mtDNA as a structural component. Methods: Neutrophils were isolated 8 trauma patients requiring orthopedic surgery postinjury and up to 5 days postoperatively. Four healthy volunteers provided positive and negative controls. Total hip replacement patients acted as an uninjured surgical control group. Neutrophil extracellular traps were visualized with DNA (Hoechst 33342TM/Sytox Green/MitoSox/MitoTracker) stains using live cell fluorescence microscopy with downstream quantitative polymerase chain reaction analysis of DNA composition. Results: Neutrophil extracellular traps were present after injury in all 8 trauma patients. They persisted for 5 days postoperatively. Delayed surgery resulted in NET resolution, but they reformed postoperatively. Total hip replacement patients developed NETs postoperatively, which resolved by day 5. Quantitative polymerase chain reaction analysis of NET-DNA composition revealed that NETs formed after injury and surgery were made of mtDNA with no detectable nuclear DNA component. Conclusions: Neutrophil extracellular traps formed after major trauma and subsequent surgery contain mtDNA and represent a novel marker of heightened innate immune activation. They could be considered when timing surgery after trauma to prevent systemic NET-induced inflammatory complications.

DOI 10.1016/j.jcrc.2014.07.013
Citations Scopus - 130Web of Science - 100
Co-authors Douglas Smith, Zsolt Balogh
2013 Kok CC, Au GG, 'Novel marker for recombination in the 3'-untranslated region of members of the species Human enterovirus A', ARCHIVES OF VIROLOGY, 158 765-773 (2013) [C1]
DOI 10.1007/s00705-012-1533-2
Citations Scopus - 6Web of Science - 5
2011 Au GG, Beagley LG, Haley ES, Barry RD, Shafren DR, 'Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18', Virology Journal, 8 1-6 (2011) [C1]
DOI 10.1186/1743-422x-8-22
Citations Scopus - 27Web of Science - 28
Co-authors Erin Harvey
2009 Haley ES, Au GG, Carlton BR, Barry RD, Shafren DR, 'Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer', Journal of Molecular Medicine, 87 385-399 (2009) [C1]
DOI 10.1007/s00109-008-0433-0
Citations Scopus - 19Web of Science - 13
Co-authors Erin Harvey
2008 Howland LJ, Au GG, Barry RD, Shafren DR, 'Potent oncolytic activity of human enteroviruses against human prostate cancer', Prostate, 68 577-587 (2008) [C1]
DOI 10.1002/pros.20741
Citations Scopus - 37Web of Science - 38
2007 Au GG, Lincz L, Enno A, Shafren DR, 'Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma', British Journal of Haematology, 137 133-141 (2007) [C1]
DOI 10.1111/j.1365-2141.2007.06550.x
Citations Scopus - 74Web of Science - 67
Co-authors Lisa Lincz
2005 Au GG, Lindberg AM, Barry RD, Shafren DR, 'Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21', International Journal of Oncology, 26 1471-1476 (2005) [C1]
Citations Scopus - 72Web of Science - 74
2004 Hansbro NG, Johansson ES, Au GG, Lindberg A, Barry RD, Shafren DR, 'Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection', Journal of Virology, 78 1431-1439 (2004) [C1]
DOI 10.1128/JVI.78.3.1431-1439.2004
Citations Scopus - 10Web of Science - 10
2004 Shafren DR, Au GG, Nguyen T, Barry RD, Hansbro NG, Harvey ES, et al., 'Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21', Clinical Cancer Research, 10 53-60 (2004) [C1]
DOI 10.1158/1078-0432.CCR-0690-3
Citations Scopus - 109Web of Science - 101
Co-authors Erin Harvey
2003 Newcombe NG, Andersson P, Johansson ES, Au GG, Lindberg AM, Barry RD, Shafren DR, 'Cellular receptor interactions of C-cluster human group A coxsackieviruses', JOURNAL OF GENERAL VIROLOGY, 84 3041-3050 (2003)
DOI 10.1099/vir.0.19329-0
Citations Scopus - 37Web of Science - 35
2000 Tooney PA, Au GG, Chahl LA, 'Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex', Neuroscience Letters, 283 185-188 (2000) [C1]
Citations Scopus - 36Web of Science - 39
Co-authors Paul Tooney
Show 23 more journal articles

Conference (14 outputs)

Year Citation Altmetrics Link
2016 Pandha HS, Annels NE, Simpson G, Mostafid H, Harrington KJ, Melcher A, et al., 'Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2016)
DOI 10.1200/JCO.2016.34.15_suppl.e16016
Citations Web of Science - 2
2016 Sahoo SS, Tanwar PS, 'Inhibition of extracellular matrix mediated TGFß signalling suppress endometrial cancer metastasis', Sydney (2016)
Co-authors Murray Cairns, Pradeep Tanwar
2015 Quay M, Wong Y, Au G, Shafren D, 'Immune-checkpoint blockade in combination with a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, significantly reduces tumor growth and tumor rechallenge', EUROPEAN JOURNAL OF CANCER (2015) [E3]
2014 Shafren D, Quah M, Wong Y, Andtbacka RH, Au G, 'Combination of a novel oncolyticimmunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model', Journal for ImmunoTherapy of Cancer, National Harbour, MD (2014) [E3]
DOI 10.1186/2051-1426-2-S3-P125
2014 Simpson GR, Ajaz M, Launchbury FA, Bolton G, Melcher AA, Harrington KJ, et al., 'Major synergy between Coxsackievirus A21 (CAVATAK (TM)) and radiotherapy or chemotherapy in bladder cancer', HUMAN GENE THERAPY, Lincoln Coll & Examinat Sch, Oxford, ENGLAND (2014) [E3]
2014 Wong YVY, Quah MY, Shafren DR, Au GG, 'Synergistic Activity of Coxsackievirus A21 (CVA21) and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)', HUMAN GENE THERAPY, Lincoln Coll & Examinat Sch, Oxford, ENGLAND (2014) [E3]
2011 Yee YWV, Chan SHE, Shafren DR, Au GG, 'Oncolytic activity of coxsackievirus A21 in human lung cancer: A novel targeted anti-cancer strategy', Journal of Thoracic Oncology, Amsterdam, The Netherlands (2011) [E3]
2011 Shafren DR, Farrelly M, Croft AJ, Davies B, Stewart J, Ingham R, et al., 'CAVATAK (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
DOI 10.1111/j.1755-148X.2011.00909.x
2011 Shafren DR, Au GG, Davies B, Chan E, Stewart J, 'Pre-clinical oncolytic activity of coxsackievirus a21 in pancreatic cancer', Annals of Oncology, Barcelona, Spain (2011) [E3]
2007 Skelding KA, Johansson ES, Au GG, Barry RD, Shafren DR, 'CAVATAK TM has anti-cancer properties against human metastatic breast cancer', Fourth International Conference on Oncolytic Viruses as Cancer Therapeutics, Carefree, Arizona (2007) [E3]
Co-authors Kathryn Skelding
2006 Au GG, Johansson ES, Berry L, Skelding KA, Haley ES, Barry RD, Shafren DR, 'Coxsackievirus A21 as an oncolytic virotherapy agent for human cancers', Northern Lights EUROPIC 2006, Inari, Finland (2006) [E3]
Co-authors Kathryn Skelding
2005 Shafren DR, Au GG, Berry LJ, Haley ES, Skelding KA, Barry RD, 'The human enterovirus, Coxsackievirus A21, exhibits oncolytic activity across a spectrum of cancer types', Proceedings of the 96th American Association for Cancer Research Annual Meeting, Anaheim, California (2005) [E3]
Co-authors Kathryn Skelding
2005 Berry LJ, Haley ES, Skelding KA, Au GG, Barry RD, Shafren DR, 'Oncolytic activity of enteroviruses across a spectrum of human cancer types', Third Annual Australian Virology Group Meeting, Phillip Island, VIC (2005) [E3]
Co-authors Kathryn Skelding
2000 Tooney PA, Au GG, Chahl LA, 'Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain', Proceedings of the Australian Physiological and Pharmacological Society Symposium Tachykinins: The Challenge Continues, Newcastle, Australia (2000) [E1]
Citations Scopus - 33Web of Science - 32
Co-authors Paul Tooney
Show 11 more conferences

Preprint (1 outputs)

Year Citation Altmetrics Link
2021 Farr R, Rootes C, Rowntree L, Nguyen T, Hensen L, Kedzierski L, et al., 'Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection (2021)
DOI 10.21203/rs.3.rs-253459/v1
Edit

Grants and Funding

Summary

Number of grants 9
Total funding $595,774

Click on a grant title below to expand the full details for that specific grant.


20113 grants / $96,500

Maitland Cancer Appeal Committee Donation - Lung Cancer Mouse Model$50,000

Funding body: Maitland Cancer Appeal Committee Incorporated

Funding body Maitland Cancer Appeal Committee Incorporated
Project Team Professor Phil Hansbro, Professor Paul Foster, Doctor Gough Au
Scheme Research Project
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100246
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

SCIREQ FlexiVentFX system + FlexiVentFX extension$45,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Professor Paul Foster, Professor Joerg Mattes, Professor Simon Keely, Professor Jay Horvat, Doctor Nicole Hansbro, Associate Professor Ming Yang, Doctor Catherine Ptaschinski, Dr KELLY Asquith, Doctor Gough Au, Conjoint Professor Peter Wark, Distinguished Emeritus Professor John Aitken, Conjoint Professor Keith Jones, Laureate Professor Roger Smith, Professor Judith Black, Professor Rakesh Kumar, Professor Paul Hertzog
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100037
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

World Cancer Congress 2011, World Expo Center, Dalian, China, 22 - 25 May 2011$1,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Gough Au
Scheme Travel Grant
Role Lead
Funding Start 2011
Funding Finish 2012
GNo G1100576
Type Of Funding Internal
Category INTE
UON Y

20101 grants / $85,188

Control of malignant glioma by naturally occurring oncolytic enteroviruses.$85,188

Funding body: Cancer Australia

Funding body Cancer Australia
Project Team Doctor Gough Au
Scheme Priority-driven Collaborative Cancer Research Scheme
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G0190325
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

20092 grants / $31,700

The use of Coxsackievirus A21 as a therapy for multiple myeloma and malignant glioma$30,000

Funding body: Ramaciotti Foundations

Funding body Ramaciotti Foundations
Project Team Doctor Gough Au
Scheme Establishment Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0189325
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

5th International Meeting on Replicating Oncolytic Virus Therapeutics, Banff Canada, 18-21 March 2009$1,700

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Gough Au
Scheme Travel Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0189949
Type Of Funding Internal
Category INTE
UON Y

20081 grants / $5,379

New Staff Grant$5,379

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Gough Au
Scheme New Staff Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0188610
Type Of Funding Internal
Category INTE
UON Y

20072 grants / $377,007

Coxsackievirus A21 virotherapy of multiple myeloma and malignant glioma$369,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Gough Au
Scheme Industry Research Fellowships
Role Lead
Funding Start 2007
Funding Finish 2010
GNo G0186779
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

The use of Coxsackie B group viruses as potential treatments for human gastric and colorectal cancers$8,007

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Gough Au
Scheme Early Career Researcher Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0188074
Type Of Funding Internal
Category INTE
UON Y
Edit

Research Supervision

Number of supervisions

Completed5
Current0

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2018 PhD Investigation of Coxsackievirus A21 as a Potential Treatment for Pancreatic Cancer PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
2017 PhD Investigating the Mechanisms of Tobacco Cigarette Smoke Induced Lung Cancer PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2016 PhD Investigation of Oncolytic Coxsackievirus A21 as a Potential Treatment for Lung Cancer PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
2016 PhD Enhancement of Oncolytic Coxsackievirus A21 with Conventional Chemotherapies and Immune Checkpoint Inhibitors for the Treatment of Melanoma PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
2014 PhD Low Pathogenic Human Enteroviruses as Novel Anti-Cancer Agents Against Malignant Glioma PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
Edit

Dr Gough Au

Position

Conjoint Senior Lecturer
Viralytics
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing

Focus area

Immunology and Microbiology

Contact Details

Email gough.au@newcastle.edu.au
Phone (02) 404 20253
Fax (02) 404 20027

Office

Room 2420
Building HMRI building
Location Level 2, HMRI Building East Wing

,
Edit